The conversion from EPO-β to DARB has the potential to maintain long term good haemoglobin control and induces significant savings for the Italian National Health System (INHS) However, the dosage needs to be adjusted on an individual basis in order to avoid excessive fluctuation of Hb concentrations. The actual conversion factor resulted on average higher than theoretical factor, settling to 240-280:1.
Conclusions
The main aim of this retrospective study was to perform a cost-minimization analysis of long term use of darbepoetin-α (DARB) after switch from erythropoietin beta (EPO-β) in treating chronic nephropathy-induced anaemia in dialysed patients. Secondary objective was the assessment of the actual EPO-β-to-DARB dose conversion factor.
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Methods
We extracted data of 78 patients who have been treated with EPO-β for at least 6 months and then switched to DARB from the database of the dialysis center of the Asti (Piedmont, Italy) hospital. From these, we selected 47 patients (23 males and 24 females) who completed a 120-weeks follow-up treatment with DARB (Table I ).
All patients were treated with a dose adjustment schedule to keep haemoglobin levels in the range 11-12g/dl. Pre-switch EPO-β administration was thrice a week, while DARB was administered once a week, both via intravenous. The initial DARB dose, chosen on the basis of the recommended conversion factor, induced an excessive erythropoietic response (Figure 2 ), which was generally followed by a gradual dose reduction (Figure 3) .
Hence, the average actual conversion factor from EPO-β to DARB at the end of 120 weeks of follow-up resulted 280 IU/mcg
In the 24 pre-switch weeks the average cost (±SD) per patient for EPO-β was 2,309.86 (±1,434.78) Euro. In the 120 weeks of follow-up the average cost (±SD) per patient for DARB/24 weeks ranged from a minimum of 1,487.09 (±1,125.51) Euro to a maximum of 2,125.73 (±1,546.85) Euro. (Table 3) The switch of 47 patients to DARB produced an overall net saving for the dialysis centre estimated in 119,540.72 Euro/120 weeks, under the hypothesis that EPO-β semester costs remain constant Weeks of Therapy before and after switch EPO -Darbepoetin alfa 
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Figure 2. Time trend of the median (1° and 3° quartiles) EPO-β and DARB doses
